Understand KRAS and the Quest for Anti-Cancer Drugs
The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/4/842 |
| id |
doaj-5fce3a84e6b74f6b88cba955e4960685 |
|---|---|
| record_format |
Article |
| spelling |
doaj-5fce3a84e6b74f6b88cba955e49606852021-04-08T23:04:06ZengMDPI AGCells2073-44092021-04-011084284210.3390/cells10040842Understand KRAS and the Quest for Anti-Cancer DrugsChang Woo Han0Mi Suk Jeong1Se Bok Jang2Institute of Systems Biology, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 46241, KoreaInstitute for Plastic Information and Energy Materials and Sustainable Utilization of Photovoltaic Energy Research Center, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 46241, KoreaDepartment of Molecular Biology, College of Natural Sciences, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 46241, KoreaThe KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.https://www.mdpi.com/2073-4409/10/4/842KRAScancersignaling pathwayinhibitors |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Chang Woo Han Mi Suk Jeong Se Bok Jang |
| spellingShingle |
Chang Woo Han Mi Suk Jeong Se Bok Jang Understand KRAS and the Quest for Anti-Cancer Drugs Cells KRAS cancer signaling pathway inhibitors |
| author_facet |
Chang Woo Han Mi Suk Jeong Se Bok Jang |
| author_sort |
Chang Woo Han |
| title |
Understand KRAS and the Quest for Anti-Cancer Drugs |
| title_short |
Understand KRAS and the Quest for Anti-Cancer Drugs |
| title_full |
Understand KRAS and the Quest for Anti-Cancer Drugs |
| title_fullStr |
Understand KRAS and the Quest for Anti-Cancer Drugs |
| title_full_unstemmed |
Understand KRAS and the Quest for Anti-Cancer Drugs |
| title_sort |
understand kras and the quest for anti-cancer drugs |
| publisher |
MDPI AG |
| series |
Cells |
| issn |
2073-4409 |
| publishDate |
2021-04-01 |
| description |
The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development. |
| topic |
KRAS cancer signaling pathway inhibitors |
| url |
https://www.mdpi.com/2073-4409/10/4/842 |
| work_keys_str_mv |
AT changwoohan understandkrasandthequestforanticancerdrugs AT misukjeong understandkrasandthequestforanticancerdrugs AT sebokjang understandkrasandthequestforanticancerdrugs |
| _version_ |
1721533332260388864 |